逆转录病毒介导的人促红细胞生成素基因在淋巴细胞中的表达

本实验设计和构建了人促红细胞生成素（Epo）重组逆转录病毒载体（LXSN-Epo）,载体中小鼠白血病病毒长末端调控序列翻译调控人Epo基因的表达。通过重组逆转录病毒,将Epo基因转导到大鼠T和B淋巴细胞中,DNA-PCR分析证明带有人Epo基因的逆转录病毒已整合到T和B淋巴细胞基因中,RT-PCR分析显示了在两种细胞中均表达了 Epo mRNA。体外生物学活性测定显示,在转导的T淋巴细胞培养上清中Epo表达水平高达243mU/ml,在感染的B淋巴细胞培养上清中Epo活性达43mU/ml。在感染的B细胞中,Epo表达在mRNA和蛋白水平均证明了逆转录病毒能有效地和迅速地转导Epo基因到新培养的B细胞中,而不需要药物选择。这些研究开始了逆转录病毒介导的基因转移走向体内Epo基因治疗研究的过程。     

Expression of the Tn antigen on erythroid cells from a patient with Tn syndrome

Summary In order to examine expression of the Tn antigen on erythroid cells from a patient with Tn syndrome, we applied a selective two phase liquid culture system for human erythroid progenitors in peripheral blood. The cells were analyzed with flow cytometry employing an anti-Tn antibody and a lectin ofVicia villosa which recognizes only the Tn determinant. In the second phase, the Tn antigen was expressed on the cultured cells from the patient on day 3 and Tn-positive cells reached 62.7% on day 9. On the other hand, Tn-positive cells were not detected in the volunteer's cultured cells. When the patient's cells were co-cultured with the cells from a healthy voluteer, the percentage of Tn-positive cells was much lower than the expected value, suggesting that the normal cells suppressed the expression of Tn antigen on the patient's cells.     

32例再生障碍性贫血的微循环及血液粘度

对３２例再障患者的甲襞、球结膜微循环及血粘度进行观察，结果表明：再障组均有不同程度的微循环异常改变（１００％），与正常对照组比较差异显著（Ｐ＜０．０１）；再障组全血粘度、全血还原粘度明显低于正常对照组（Ｐ＜０．０１），再障患者的Ｈｂ与全血粘度及血浆比粘度呈正相关。     

EIAV减毒疫苗诱导马外周血单个核细胞Th1型细胞因子的转录

目的：探讨马传染性贫血病毒驴白细胞减毒疫苗免疫马后,外周血单个核细胞中Th1型细胞因子转录水平与免疫保护应答的关系,揭示DLV的免疫保护机制。方法：应用分子克隆及实时定量RT-PCR技术,建立了马PBMC中IFNγ-、IL-2、IL-12 mRNA转录水平的定量检测方法,定期观察4组（疫苗免疫组、阴性对照组、强毒株阳性对照组、自然感染组）12匹马外周血PBMC中细胞因子的转录水平及分布特征,同时监测体温变化等指标。疫苗株免疫动物8个月后,用EIAV强毒株攻击,观察攻击前后细胞因子转录水平的变化。结果：DLV免疫马,在免疫后3周外周血PBMC中IFN-γ、IL-2转录量显著高于阴性对照组及自然感染组（P〈0.01）;免疫后用EIAV强毒株攻击,IFNγ-、IL-2和IL-12转录的量明显升高,免疫马获得完全保护;强毒株攻击阳性对照马IFN-γ、IL-2转录量随疾病进展波动,发热期下降。结论：本研究首次证明EIAV减毒疫苗可诱导马外周血PBMC中IFN-γ、IL-2、IL-12基因高效转录,其转录水平与DLV的免疫保护密切相关,此结果在分子水平为阐明DLV的免疫保护机制提供了新的实验依据。     

缺铁性贫血对学龄儿童某些认知能力影响的研究

本文采用双盲法对 IDA 和 NIDA学龄儿童各61名进行了认知能力测验及铁治疗前后的动态比较。结果表明:IDA 儿童识记再认、字母匹配反应时、数字扫描记忆和一般推理能力测验成绩较 NIDA 儿童差。经铁治疗的IDA 儿童,注意、短时记忆和心理动作反应速度均有明显提高。但对较高级认知能力的改善不明显。     

Bone marrow mast cell reaction in preleukaemic myelodysplasia and in aplastic anaemia

Summary The relationship of bone marrow mast cell counts to prognosis was investigated in 48 patients with preleukaemic myelodysplasia, in 59 patients with aplastic anemia and in a DMBA induced myelodysplasia/leukaemia rat model. In patients with myelodysplasia terminating in overt leukaemia the number of mast cells per square millimeter was not correlated to duration of the preleukaemic course. Leukaemia development probabilities of patients at risk were not different for low and elevated mast cell counts. In aplastic anaemia, however, a lower bone marrow mast cell count was related to a higher survival probability and longer survival time. In the animal model no significant differences could be found between myelodysplastic, leukaemic, and control animals.     

高通量透析可改善维持性血液透析患者肾性贫血

目的 探讨高通量透析对维持性血液透析患者肾性贫血的防治作用及其机制。方法 55例患者随机分为高通量透析组(HPD组)与常规血液透析组(CHD组)，HPD组患者使用聚砜膜F60高通量透析器，CHD组患者使用低通量F6透析器治疗，检测首次透析前后两组患者血尿素氮(BUN)、肌酐(Cr)、K^ 、Na^ 、Cl^-、Ca^2 、P^3-、甲状旁腺素(PTH)，以及透析前后血浆细胞因子(IL-1β、IL-6、IL-8、TNF-α)和透析开始20min后透析废液中上述细胞因子含量，动态观察并记录患者主诉，动态检测透析前后血红蛋白、红细胞压积，透析治疗1年后，复测并比较两组患者临床生化指标。结果 ①HPD组对PTH、P清除高于CHD组(P＜0．05)，透析1年后，HPD组血浆PTH、P水平明显低于CHD组(P＜0．05)。②透析后即刻HPD组透析废液中细胞因子含量显著高于CHD组(P＜0．05)；透析治疗1年后HPD组血浆细胞因子水平呈下降趋势，但与治疗前比较，无统计学意义(P＞05)。③透析后即刻，HPD组与CHD组血红蛋白、红细胞压积水平与透析前比较均呈上升趋势，但无统计学意义(P＞0．05)，两组间比较差异不显著；透析1年后，HPD组血红蛋白、红细胞压积水平较透析前水平变化差异显著(P＜0．05)，两组间比较显著升高(P＜0．05)。结论 HPD可改善维持性血液透析患者的肾性贫血，其机制与HPD能清除一些不易被CHD透析清除、且对红细胞生成和成熟有抑制作用的蛋白类大中分子物质，主要是PTH、精胺、聚胺、细胞因子等有关。     

Purine nucleoside phosphorylase deficiency: a new case report and identification of two novel mutations (Gly156A1a and Val217Ile), only one of which (Gly156A1a) is deleterious

Purine nucleoside phosphorylase (PNP) deficiency results in an autosomal recessive immunodeficiency disease characterized by initial involvement of cellular immunity and neurological manifestations with subsequent abnormalities of humoral immunity. The initial presentation and clinical course has varied widely in the relatively few published cases. The molecular basis has been reported in only 10 patients, precluding evaluation of phenotype-genotype relationships. We now report clinical, immunologic, and molecular findings in a new case of relatively early onset that emphasizes hypotonia and developmental delay as early manifestations. The patient carried two novel missense mutations (Gly56A1a and Val217Ile) on the same allele in apparent homozygosity. Expression of each of the mutant enzymes in vitro demonstrated that the Gly156A1a mutation abolished enzyme activity while the Val217Ile mutation was without obvious effect and is therefore a normal variant. Such "normal" polymorphisms might be associated with a variable response to the immunosuppressive PNP inhibitors currently in clinical trials.     

Erythropoiesis in patients with aggressive and indolent non-Hodgkin’s lymphomas

Parameters of the erythroid, granulocytic, and megakaryocytic hemopoietic stems were compared in 87 patients with aggressive and indolent non-Hodgkins lymphomas before and 6 months after the start cytostatic therapy. Before chemotherapy anemia was detected in 46% patients with aggressive and 49% patients with indolent lymphomas. Hemoglobin content, peripheral blood erythrocyte count, and total count of erythroid cells in the bone marrow increased during chemotherapy in the indolent lymphoma group. Increased count of erythroid cells in the myelogram was due to decreased count of lymphoid cells in the bone marrow, which was associated with complete or partial remission. In aggressive lymphoma chemotherapy decreased the mean level of hemoglobin and mean erythrocyte count in the peripheral blood, but the total count of erythroid cells in the bone marrow increased; no relationship was detected between lymphocyte count in the bone marrow and erythropoiesis characteristics. Lymphocytosis >50% in the myelogram before chemotherapy was less frequent in this group in comparison with indolent non-Hodgkins lymphomas.Translated from Byulleten Eksperimentalnoi Biologii i Meditsiny, Vol. 138, No. 12, pp. 668–673, December, 2004This revised version was published online in April 2005 with a corrected cover date.     

再生障碍性贫血患者淋巴细胞表型变化

目的：研究再生障碍性贫血（AA）患者骨髓（BM）及外周血（PB）淋巴细胞及其活化相关分子的表达及临床意义。方法：采用单色和双色免疫荧光标记法，流式细胞仪分析AA患者的BM和PB中淋巴细胞膜分子的表达。结果：AA患者BM和BP中CD8^ 细胞增加，CD4／CD8比例下降，BM在CD25^ 细胞和HLA－DR^ 细胞增多，急性AA增加尤为显著（P＜0．01），BM中CD16^ 或CD56^ 细胞也明显增多（P＜0．05），双标记分析提示T细胞主要为CD8^ 细胞：急性AA患者CD8^ -CD25^ 细胞显著增多（P＜0．01），AA患者BM中淋巴细胞活化相关分子表达增多，尤其4－1BB^ ,CD95L^ 和CD40L＋细胞显著增多（P＜0．01），结论：AA患者BM中淋巴细胞活化相关膜分子增多，是AA免疫功能异常及最终导致造血功能衰竭的原因之一。